{
    "2018-10-03": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Boston Pharma Adds to War Chest in Pacts With Novartis, GlaxoSmithKline",
                "features": {
                    "keywords": [
                        "Boston Pharma",
                        "Novartis",
                        "GlaxoSmithKline",
                        "War Chest",
                        "Pacts"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Ultra Rapid Lispro",
                        "Diabetes",
                        "Studies",
                        "Succeeds"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "diabetes"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Boston Pharma",
                        "Anti-Infective",
                        "Drugs",
                        "Deal"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "anti-infective"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Merck & Other Pharma Players Await FDA Decisions in October",
                "features": {
                    "keywords": [
                        "Merck",
                        "Pharma",
                        "FDA",
                        "Decisions",
                        "Await"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "regulatory"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",
                "features": {
                    "keywords": [
                        "Endologix",
                        "Q3 Sales",
                        "Obseva",
                        "Trial Results",
                        "Positive",
                        "Kala",
                        "Shares"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "sales",
                        "trials"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Novartis Licenses Three Novel Anti-infective Programs To Boston Pharma",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Anti-infective",
                        "Programs",
                        "Licenses",
                        "Boston Pharma"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "anti-infective"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}